Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28152248 | 0.87 | MGAM (0.62) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL23391807 | 0.83 | MGAM (0.44) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL112862 | 0.81 | — | — | |
| SCHEMBL28567697 | 0.81 | LMNA (0.41) | TSHRALDH1A1TDP1CYP2C19HSD17B10 | |
| SCHEMBL11911037 | 0.81 | MGAM (0.42) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL9074339 | 0.81 | TSHR (0.59) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL1924519 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TDP1CYP2C19MMP1MMP2 | |
| SCHEMBL29309522 | 0.81 | MGAM (0.38) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL15344 | 0.79 | GAA (0.58) | MGAMGAASIMGAM2TSHR | |
| Hydrochloric Acid SCHEMBL30578737 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570313-A2 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025042896-A1 | DNA TOPOISOMERASE IIβ INHIBITORS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20230365533-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-20 | — | — | US | disclosed |
| CN-106661395-B | Workpiece fixing sheet with resin layer | 琳得科株式会社 | 2021-05-28 | — | — | CN | disclosed |
| EP-3475276-B1 | THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER | US HEALTH (US) | 2021-03-31 | — | — | EP | disclosed |
| US-10836759-B2 | Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2020-11-17 | — | — | US | disclosed |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-07-07 | — | — | US | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-7169774-B2 | Cephalotaxane derivatives and their processes of preparation and purification | STRAGEN PHARMA S.A. (CH) | 2007-01-30 | — | — | US | disclosed |
| WO-2006090915-A1 | PYRIDYL ACETIC ACID COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-31 | — | — | WO | disclosed |
| EP-1685092-A2 | ASYMMETRIC REDUCTIVE AMINATION OF KETO ACID DERIVATIVES FOR PRODUCING AMINO ACID DERIVATIVES | Takasago International Corporation (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-20060135530-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | US | disclosed |
| US-20060122225-A1 | Method for producing an optically active tetrahydroquinoline | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1594843-A2 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | Takasago International Corporation (JP) | 2005-11-16 | — | — | EP | disclosed |
| EP-1527049-A2 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2005-05-04 | — | — | EP | disclosed |
| WO-2005028419-A2 | ASYMMETRIC REDUCTIVE AMINATION OF KETO ACID DERIVATIVES FOR PRODUCING AMINO ACID DERIVATIVES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004074255-A2 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE TETRAHYDROQUINOLINE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004014860-A2 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | MGAM 328/4885GAA 343/4885SI 429/4885 |
| US-20230365533-A1 | BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, CRHR1 | MGAM 4821/4885GAA 3466/4885SI 3534/4885 |
| US-10836759-B2 | Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer | IDH1, IDH2, IDH3B | MGAM 4622/4885GAA 4210/4885SI 4830/4885 |
| US-20060122225-A1 | Method for producing an optically active tetrahydroquinoline | AADAT, KMO, ALDH7A1 | MGAM 2405/4885GAA 1242/4885SI 1115/4885 |
| US-20060135530-A1 | Fused heterocyclic compounds | NR4A3, DPP3, INSR | MGAM 940/4885GAA 751/4885SI 201/4885 |
| US-11680060-B2 | Bicycloheptane pyrrolidine orexin receptor agonists | HCRTR1, HCRTR2, CRHR1 | MGAM 4778/4885GAA 3350/4885SI 3644/4885 |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | IDH1, IDH3B, IDH3A | MGAM 2194/4885GAA 141/4885SI 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.